background surfactant protein d deficient mice develop pathology associated focal accumulations foamy alveolar macrophages excess surfactant phospholipids alveolar space hypertrophy hyperplasia alveolar type ii cells findings associated chronic inflammatory state treatment deficient mice truncated recombinant fragment human rfhspd shown decrease lipidosis alveolar macrophage accumulation production proinflammatory chemokines aim study investigate treatment reduces structural abnormalities parenchymal architecture type ii cells characteristic deficiency methods mice aged NUMBER weeks NUMBER weeks NUMBER weeks treated NUMBER NUMBER NUMBER weeks respectively mice sacrificed age NUMBER weeks compared pbs treated deficient groups lung structure quantified stereology light electron microscopic level emphasis quantification emphysema type ii cell changes intracellular surfactant data analysed sided mannwhitney main results NUMBER weeks treatment alveolar number higher mean alveolar size smaller compared knockout controls significant difference concerning indices pulmonary emphysema treated groups type ii cell number size smaller consequence treatment total volume lamellar bodies type ii cell lung smaller NUMBER weeks treatment conclusion treatment deficient mice leads reduction degree emphysema correction type ii cell hyperplasia hypertrophy supports concept therapeutic option diseases characterized decreased spd levels lung sp d emphysema like sp d sp d rfhsp d sp d sp d rfhsp d sp d wild type design based non parametric u test saline treated knock rfhsp d sp d rfhsp d rfhsp d sp d